Bardin Hill Management Partners’s Prevail Therapeutics Inc. Common Stock PRVL Stock Holding History

Bardin Hill Management Partners’s Portfolio PRVL Stock Details PRVL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-206,867	Closed	-$4.77M	–	110
2020 Q4	$4.77M	Buy	+206,867	New	+$2.62M	1%	27

Bardin Hill Management Partners's PRVL Position: Q1 2021 in Review

Bardin Hill Management Partners sold out of Prevail Therapeutics Inc. Common Stock (PRVL) in Q1 2021, closing a stake of 206,867 shares — an estimated $4.77M sold.

Bardin Hill Management Partners first reported a position in PRVL in Q4 2020 and held it in 1 quarter. The position peaked at $4.77M in Q4 2020. 0 funds tracked by Wall St. Rank hold PRVL as of Q1 2021.

Bardin Hill Management Partners reported no remaining Prevail Therapeutics Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
Bardin Hill Management Partners sold 206,867 Prevail Therapeutics Inc. Common Stock shares in Q1 2021, an estimated $4.77M.
Bardin Hill Management Partners first reported a position in Prevail Therapeutics Inc. Common Stock in Q4 2020 and held it in 1 quarter.
Bardin Hill Management Partners's Prevail Therapeutics Inc. Common Stock position peaked at $4.77M in Q4 2020.
0 funds tracked by Wall St. Rank held Prevail Therapeutics Inc. Common Stock as of Q1 2021.

Based on Bardin Hill Management Partners's 13F filing for Q1 2021, filed 14 May 2021.